Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,487 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline for Injection Clear all
Completed Not applicable Interventional Results available

Epidural Lavage Study for Lumbar Stenosis

NCT03511053
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Epidural Steroid Injection with Lavage
Procedure
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

NCT02623829
View directory record Official record
Conditions
Post-operative Excessive Scarring
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 25, 2026, 12:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

NCT05139030
View directory record Official record
Conditions
Knee Osteoarthritis, Pain Management
Interventions
bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 25, 2026, 12:33 AM EDT
Completed No phase listed Observational

Predictive Factors for LBP Interventional Treatment Outcomes

NCT02329951
View directory record Official record
Conditions
Low Back Pain, Lumbar Radiculopathy
Interventions
Facet intervention, Sacroiliac joint injection, Epidural steroid injection
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 3 Interventional

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

NCT03617367
View directory record Official record
Conditions
Cervical Dystonia
Interventions
daxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

NCT00752297
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Preservative-free Saline, Mentor Purified Toxin
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Versus Interscalene Nerve Block

NCT03929146
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Exparel, Interscalene Nerve Block
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 25, 2026, 12:33 AM EDT
Completed No phase listed Observational

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

NCT00940199
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 1 Interventional

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

NCT03875664
View directory record Official record
Conditions
Postoperative Pain
Interventions
Liposomal bupivacaine, Placebo - injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

NCT03058692
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01371305
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 84 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 4 Interventional

Paracervical Block for Pain Reduction in Saline Infusion Sonograms

NCT07048769
View directory record Official record
Conditions
Pain During Saline Infusion Sonogram
Interventions
Lidocaine, Sham paracervical block
Drug · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartsdale, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Terminated Phase 4 Interventional

Pain Management After Total Shoulder Arthroplasty

NCT03219983
View directory record Official record
Conditions
Glenohumeral Arthritis, Total Shoulder Arthroplasty
Interventions
Ropivacaine, liposomal bupivacaine
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940886
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
114
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Adductor Canal Block Versus Liposomal Bupivacaine in TKA

NCT04086186
View directory record Official record
Conditions
Total Knee Arthroplasty, Post-operative Pain Control
Interventions
Liposomal Bupivacaine Peri-articular Injection, Adductor canal block
Procedure
Lead sponsor
Good Samaritan Regional Medical Center, Oregon
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 1 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

NCT07253662
View directory record Official record
Conditions
Adenocarcinoma Pancreas
Interventions
PIPAC, Nab-paclitaxel
Device · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 12:33 AM EDT